Arkin Holdings

Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.

Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.

Revisto is a pioneering AI-powered technology that simplifies the medical, legal, and regulatory (MLR) review process for pharmaceutical marketing materials.

Phytolon Ltd, founded in 2000 and based in Misgav, Israel, specializes in the development of natural food colorants. The company has established a novel and sustainable technology that utilizes fermentation processes with baker’s yeast cells as biofactories to produce high-quality, plant-based food colors. This innovative approach provides a healthy alternative to synthetic food dyes, offering food manufacturers safe, cost-effective, and stable all-natural colors. Phytolon is dedicated to promoting human health and environmental sustainability through scientific advancement in the food color industry.

Bluejay Therapeutics is a biopharmaceutical company dedicated to developing cures for infectious diseases, with a primary focus on chronic Hepatitis B. This condition poses a significant global health challenge, and the company aims to address the urgent need for effective treatments. Bluejay is advancing two innovative therapeutic approaches: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class oral small molecule inhibitors targeting HBsAg. These strategies are designed to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially leading to a functional cure for patients. Additionally, the company’s research encompasses therapeutic options for chronic Hepatitis D, further solidifying its commitment to improving immunity and recovery for individuals affected by serious viral and liver diseases.

Honeycomb, formerly known as Agilius, operates an insurance technology platform that specializes in real estate insurance services. Founded in 2019 and based in San Francisco, California, the company offers a streamlined online process for homeowners associations, property managers, developers, and building owners to purchase master insurance policies for condominium and apartment buildings in under three minutes. By leveraging advanced technologies such as aerial photography, computer vision, artificial intelligence, and machine learning, Honeycomb eliminates the need for on-site inspections, allowing users to obtain instant, hassle-free quotes and manage their policies efficiently. This innovative approach aims to bring simplicity and transparency to the real estate insurance market, providing significant cost savings for its clients.

Reunion Neuroscience is a clinical-stage pharmaceutical company dedicated to developing therapeutic solutions for underserved mental health conditions. The company's lead product, RE104, is a proprietary serotonergic psychedelic compound aimed at providing a fast-acting and durable antidepressant option for individuals suffering from postpartum depression and other mental health issues. Additionally, Reunion is advancing the RE200 series, which includes compounds designed for more selective serotonin receptor activity and reduced psychoactivity, potentially broadening their application in chronic treatment paradigms and various mental health conditions.

Nocion Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, established in 2017. The company focuses on developing novel therapeutics called "nocions," which are designed to treat conditions associated with neurogenic inflammation. These nocions specifically target activated sensory neurons, entering nociceptors through large-pore channels that open in response to stimulation. This mechanism allows for the selective blocking of sodium channels, providing targeted and sustained relief for serious conditions such as cough, itch, pain, and inflammation. By offering an alternative to traditional small molecule anesthetics, Nocion Therapeutics aims to deliver more effective treatment options for patients suffering from these debilitating symptoms.

Siftwell operates as a predictive analytics company in the healthcare sector, utilizing artificial intelligence and machine learning to analyze extensive datasets, including health plan data, claims, and social determinants of health. The company focuses on identifying members at high risk for rising costs, declining health, and potential churn. By enhancing data-driven decision-making, Siftwell enables clients to improve member health outcomes, reduce healthcare costs, and enhance quality metrics, ultimately fostering greater member retention. Their unique expertise combines technology with managed care, allowing for an effective approach to solving complex challenges in the healthcare industry.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Human Immunology Biosciences is a biotechnology company dedicated to developing therapies for immune-mediated diseases, particularly autoimmune and inflammatory conditions. The company specializes in precision medicine and focuses on discovering and creating transformative therapies. Its lead product, felzartamab, is a fully human anti-CD38 monoclonal antibody that has demonstrated the ability to deplete CD38+ cells, including plasma cells and natural killer cells, in clinical studies. This mechanism may enhance clinical outcomes across a range of immune-mediated diseases, offering improved treatment options for patients suffering from these conditions.

Eleos Health develops innovative health technology solutions aimed at enhancing decision-making for clinicians in the behavioral health sector. The company's AI-powered Speech-to-Insights system operates during mental health sessions to analyze voice data in real time. By gathering insights on patients through this voice technology, Eleos Health enables clinicians to deliver personalized, efficient, and cost-effective care. The automated nature of the system helps streamline the clinical process, ultimately supporting mental health professionals in providing the necessary care and support for their patients.

MadeRight is a company based in San Mateo, California, that specializes in manufacturing and selling a diverse range of products, including apparel, jewelry, and accessories. These products encompass tops, bottoms, jackets, outerwear, and various types of footwear and fabrics. In addition to its apparel business, MadeRight focuses on sustainability by offering a natural additive derived from fungi grown on industrial waste. This additive enhances the performance of bio-plastics, making them more effective and environmentally friendly. It provides improvements in physical attributes and functional performance, such as anti-microbial properties and heat resistance, while remaining scalable and affordable for use in sustainable packaging solutions.

Percepto is a developer of autonomous drone technology for inspection and surveillance. The company is at the forefront of redefining how industrial sites and critical infrastructure are holistically inspected and monitored, harnessing remote robotics to autonomously collect, aggregate, and analyze visual data. Leveraging its experience with Percepto Sparrow, the first deployed drone-in-a-box solution on the market, Percepto introduced Percepto AIM (Autonomous Inspection and Monitoring), the first end-to-end autonomous inspection and monitoring platform. Percepto AIM empowers the remote operation center of the future to assess risk, minimize downtime, drive efficiency, increase safety, and reduce operational costs.

Revamp Medical, founded in 2016, focuses on addressing the urgent unmet needs of patients suffering from acute heart failure, a condition that leads to over one million annual hospital admissions in the United States and incurs significant healthcare costs. The company has developed the Doraya™ catheter, a patented device designed to regulate vascular hemodynamics in these patients. This innovative solution targets issues such as diuretic resistance by managing preload and reducing central venous pressure, ultimately enhancing the efficacy of diuretics and facilitating progressive decongestion. Revamp Medical is backed by a team of experienced professionals with a strong background in medical technology startups, positioning the company to deliver an easily adoptable treatment option that addresses a critical gap in heart failure care.

Pigmentum is an agricultural technology company focused on developing a molecular technology platform that facilitates external gene activation in plants. This innovative mechanism allows for the crossbreeding and assimilation of genetic elements, leading to the creation of unique seeds. By enabling agricultural companies to manipulate genetic traits, Pigmentum supports the large-scale production of natural compounds applicable in the food, pharmaceutical, and cosmetic industries. This technology offers a new approach to enhancing plant characteristics, thereby contributing to advancements in agricultural practices.

Nest Genomics is a lab-agnostic, comprehensive software solution for implementing genomic programs at scale.

Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed to create enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins.

Validic, Inc. is a technology company specializing in a cloud-based platform that collects and manages mobile health data from various internet-enabled applications and devices. Founded in 2010 and based in Durham, North Carolina, Validic connects healthcare organizations with over 400 clinical and consumer devices, allowing for the integration of patient-recorded data into clinical workflows. Its primary offerings include Validic Solution, which links digital health data to healthcare providers; Validic Connect, which facilitates access to a broader range of clinical and consumer applications; and Validic Mobile, designed for data collection from health apps and in-home devices. The company serves a diverse clientele, including wellness companies, healthcare providers, pharmaceuticals, and health plans, with the goal of enhancing the quality of human life through actionable health data.

Photys Therapeutics is a biopharmaceutical company focused on developing bifunctional small molecules that provide precise control over protein post-translational modifications. This innovative platform allows for the restoration of protein function, repair of cellular signaling pathways, and enhancement of the body's natural disease-fighting abilities. Co-founded by prominent chemist Amit Choudhary from the Broad Institute and the Longwood Fund, Photys is supported by a scientific advisory board that includes renowned experts from institutions such as MIT, Salk Institute, and Berkeley. The company's unique approach aims to advance therapeutic options in the healthcare industry, particularly by targeting kinases and potentially phosphatases, to address various diseases effectively.

Welcome Homes is an online platform designed to simplify the home building process for buyers. By streamlining various stages, including land selection, customization, financing, and construction, it allows users to manage their home-building journey entirely online. This approach transforms home buyers into home builders, providing a seamless and price-transparent experience. Welcome Homes aims to help individuals save time and ensure they can create a beautifully designed home in their preferred location.

Bluejay Therapeutics is a biopharmaceutical company dedicated to developing cures for infectious diseases, with a primary focus on chronic Hepatitis B. This condition poses a significant global health challenge, and the company aims to address the urgent need for effective treatments. Bluejay is advancing two innovative therapeutic approaches: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class oral small molecule inhibitors targeting HBsAg. These strategies are designed to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially leading to a functional cure for patients. Additionally, the company’s research encompasses therapeutic options for chronic Hepatitis D, further solidifying its commitment to improving immunity and recovery for individuals affected by serious viral and liver diseases.

Virility Medical is focused on developing an innovative intimate skin patch aimed at addressing premature ejaculation. The patch incorporates an electronic module that delivers neuromuscular electrical stimulation through the skin to the surrounding muscles. This method is designed to help men manage and delay the onset of premature ejaculation, effectively treating male sexual dysfunction. By utilizing neuromodulation technology, Virility Medical aims to provide a discreet and effective solution for individuals seeking assistance with this common concern.

Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.

Phytolon Ltd, founded in 2000 and based in Misgav, Israel, specializes in the development of natural food colorants. The company has established a novel and sustainable technology that utilizes fermentation processes with baker’s yeast cells as biofactories to produce high-quality, plant-based food colors. This innovative approach provides a healthy alternative to synthetic food dyes, offering food manufacturers safe, cost-effective, and stable all-natural colors. Phytolon is dedicated to promoting human health and environmental sustainability through scientific advancement in the food color industry.

The value of connecting disparate datasets is immense, yet much of this potential remains untapped. Imagine the transformative possibilities: pharmaceutical companies sharing data to design better drugs and evaluate their real-world value, hospitals and HMOs diagnosing rare diseases faster, or financial institutions collaborating to combat financial crime. Rhino Federated Computing makes this vision a reality. Our federated computing platform, powered by advanced edge-computing and federated learning technologies, enables organizations to train and deploy AI models on massive, distributed datasets—without sharing sensitive information or compromising data privacy and sovereignty. This breakthrough approach was pioneered by our co-founder and CEO, Dr. Ittai Dayan, a recognized leader in the field whose work includes a landmark Nature Medicine publication in 2021.

Fu-Gen is an independent power producer and renewable energy investor focused on developing a comprehensive renewable energy network. The company specializes in greenfield projects and invests in various stages of renewable energy initiatives, from pre-permit phases to operational wind and solar assets. Its portfolio includes solar, wind, and storage-based projects aimed at achieving grid parity. By optimizing these renewable energy assets, Fu-Gen supports the transition to a low-carbon economy in Europe while providing sustainable returns to its investors.

Eleos Health develops innovative health technology solutions aimed at enhancing decision-making for clinicians in the behavioral health sector. The company's AI-powered Speech-to-Insights system operates during mental health sessions to analyze voice data in real time. By gathering insights on patients through this voice technology, Eleos Health enables clinicians to deliver personalized, efficient, and cost-effective care. The automated nature of the system helps streamline the clinical process, ultimately supporting mental health professionals in providing the necessary care and support for their patients.

Mindspace Ltd. is a provider of high-end co-working office spaces and rooms, catering to a diverse clientele that includes entrepreneurs, freelancers, startups, and established enterprises. Founded in 2013 and headquartered in Tel Aviv, Israel, the company operates additional locations in cities such as Herzliya, Warsaw, London, Washington, San Francisco, Berlin, Hamburg, and Munich. Mindspace offers a range of flexible workspace solutions, including open spaces, private offices, meeting rooms, and event venues, designed to meet the varying needs of teams of all sizes. The company emphasizes beautifully designed environments and a personalized level of service, fostering enhanced employee engagement and a strong sense of community. With a presence in over 40 locations across 20 cities and 7 countries, Mindspace aims to redefine the workplace experience, accommodating the evolving ways in which people work and collaborate.

Eleos Health develops innovative health technology solutions aimed at enhancing decision-making for clinicians in the behavioral health sector. The company's AI-powered Speech-to-Insights system operates during mental health sessions to analyze voice data in real time. By gathering insights on patients through this voice technology, Eleos Health enables clinicians to deliver personalized, efficient, and cost-effective care. The automated nature of the system helps streamline the clinical process, ultimately supporting mental health professionals in providing the necessary care and support for their patients.

Lendbuzz, Inc. operates an innovative car financing platform that utilizes machine learning algorithms to assess the creditworthiness of individuals, particularly those with thin or no credit history. Founded in 2015 and based in Boston, Massachusetts, the company focuses on providing financing solutions for consumers who are often underserved by traditional banks, including international students, foreign professionals, and expatriates. By analyzing a range of background information—such as employment, education, and financial history—Lendbuzz is able to extend loans and refinancing options with favorable terms, regardless of credit score or the presence of a social security number. The platform partners with auto dealerships to facilitate access to financing, allowing consumers to purchase vehicles while enabling dealerships to serve a broader and more diverse client base.

Laguna Health offers AI-powered contextual care management services designed to enhance personalized healthcare, particularly during hospital transitions. By leveraging advanced natural language processing and AI technology, Laguna Health provides care managers with a tool that improves efficiency and consistency in responding to individual patient needs. The company's solution integrates seamlessly with existing platforms and workflows, eliminating the need for additional integration. Supported by published clinical research and partnerships with national health plans, Laguna Health demonstrates its effectiveness in driving cost savings and productivity gains for care managers. This approach ultimately helps employers and integrated delivery networks improve health outcomes for their members while streamlining care management processes.

Edocate operates a medical simulation platform focused on chronic disease management and medical education. The platform allows users to create unique virtual patient cases across various therapeutic areas, facilitating engagement with healthcare professionals. It offers self-based learning tools for continuous training and assessment, enabling medical education providers to develop and disseminate their own educational content efficiently. Additionally, Edocate's platform provides insights into healthcare professional decision-making, clinical gaps, variability in care, prescription patterns, guideline compliance, and patient outcomes, contributing to improved healthcare delivery.

MedMinder Systems, Inc. specializes in developing products for pill dispensing, medication management, and adherence support. The company offers a range of solutions including automatic pill dispensers that provide reminders through visual and auditory alerts, as well as notifications for caregivers and family members to monitor medication usage remotely. MedMinder's product lineup includes locked pill dispensers, medical alert devices, and pre-filled trays designed for various forms of medication such as pills and capsules. Established in 2007 and headquartered in Needham, Massachusetts, MedMinder serves customers across several states including Massachusetts, New York, Florida, and Pennsylvania, among others. The company's mission is to simplify the medication management process and enhance adherence for users.

The value of connecting disparate datasets is immense, yet much of this potential remains untapped. Imagine the transformative possibilities: pharmaceutical companies sharing data to design better drugs and evaluate their real-world value, hospitals and HMOs diagnosing rare diseases faster, or financial institutions collaborating to combat financial crime. Rhino Federated Computing makes this vision a reality. Our federated computing platform, powered by advanced edge-computing and federated learning technologies, enables organizations to train and deploy AI models on massive, distributed datasets—without sharing sensitive information or compromising data privacy and sovereignty. This breakthrough approach was pioneered by our co-founder and CEO, Dr. Ittai Dayan, a recognized leader in the field whose work includes a landmark Nature Medicine publication in 2021.

Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.

BioSight is a biopharmaceutical company focused on developing innovative cancer-targeted chemotherapy pro-drugs. Founded in 2000 and based in Lod, Israel, BioSight has developed a technology known as S2DOT, which allows for the targeted delivery of chemotherapy drugs directly into cancer cells. This approach significantly reduces the systemic toxicity often associated with traditional chemotherapy treatments. The company’s lead product is a non-toxic conjugate of cytarabine and asparagine, designed specifically for the treatment of acute myeloid leukemia. Through its research and development efforts, BioSight aims to provide safe and effective therapeutic options for patients suffering from hematological malignancies and disorders.

Percepto is a developer of autonomous drone technology for inspection and surveillance. The company is at the forefront of redefining how industrial sites and critical infrastructure are holistically inspected and monitored, harnessing remote robotics to autonomously collect, aggregate, and analyze visual data. Leveraging its experience with Percepto Sparrow, the first deployed drone-in-a-box solution on the market, Percepto introduced Percepto AIM (Autonomous Inspection and Monitoring), the first end-to-end autonomous inspection and monitoring platform. Percepto AIM empowers the remote operation center of the future to assess risk, minimize downtime, drive efficiency, increase safety, and reduce operational costs.

Pixellot is a sports media company based in Tel Aviv, Israel, that specializes in automatic production solutions for amateur and semi-professional sports events. Founded in 2014 by experts in video and media technology, Pixellot utilizes patented technology to streamline the production workflow through an unmanned multi-camera system that captures the entire field. This innovative approach, supported by advanced algorithms, allows for dynamic coverage of gameplay and the generation of highlights. The company streams over 11,000 live video hours monthly to fans, players, and coaches across various platforms. With over 2,000 systems sold globally, Pixellot serves minor leagues, high schools, youth academies, and top clubs, collaborating with notable partners such as ESPN and Sporttotal.tv. The company also provides services to prestigious teams like Bayern Munich and Real Sociedad, enhancing the visibility and reach of sports at various levels.

Redpin Therapeutics is a preclinical stage gene therapy company based in New York, founded in 2017. The company specializes in developing a proprietary chemogenetics platform designed to create targeted cell therapies for intractable diseases of the nervous system. Its innovative approach combines principles from synthetic biology, gene therapy, and conventional pharmacotherapy, utilizing ion channels as neuromodulation tools. This enables selective activation or inhibition of disease-causing neurons, allowing for precise regulation of dysfunctional neuronal circuits while sparing healthy cells. Through its research and development efforts, Redpin Therapeutics aims to provide new treatment options for challenging neurological conditions.

BioSight is a biopharmaceutical company focused on developing innovative cancer-targeted chemotherapy pro-drugs. Founded in 2000 and based in Lod, Israel, BioSight has developed a technology known as S2DOT, which allows for the targeted delivery of chemotherapy drugs directly into cancer cells. This approach significantly reduces the systemic toxicity often associated with traditional chemotherapy treatments. The company’s lead product is a non-toxic conjugate of cytarabine and asparagine, designed specifically for the treatment of acute myeloid leukemia. Through its research and development efforts, BioSight aims to provide safe and effective therapeutic options for patients suffering from hematological malignancies and disorders.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, specifically anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapy aimed at treating anemia caused by elevated hepcidin levels, as well as fibrodysplasia ossificans progressiva. Another candidate, KER-012, is being developed for conditions related to bone loss, such as osteoporosis and osteogenesis imperfecta, and for pulmonary arterial hypertension. Founded in 2015, Keros Therapeutics is headquartered in Lexington, Massachusetts.

Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Utilizing a proprietary platform that integrates computational biology, genomics, and metabolomics, Metabomed identifies specific metabolic alterations associated with cancer growth. The company's small molecule drugs are designed to halt the proliferation of reprogrammed cancer cells, which allows oncologists to initiate treatment more swiftly and enhances the chances of successful patient outcomes while minimizing harm to healthy tissues. Through its innovative approach, Metabomed aims to advance cancer treatment by addressing the metabolic characteristics that distinguish cancer cells from normal cells.

Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics that enhance the body’s immune response to cancer. Founded in 2017, the company utilizes its proprietary PREDATOR platform to engineer conditionally activated molecules, known as INDUKINE molecules. These therapeutics are designed to remain inactive in peripheral tissues but activate selectively within the tumor microenvironment, addressing the limitations of traditional proinflammatory immune therapies. By stimulating both adaptive and innate immunity, Werewolf Therapeutics aims to improve cancer treatment outcomes.

Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and has operated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, specifically anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapy aimed at treating anemia caused by elevated hepcidin levels, as well as fibrodysplasia ossificans progressiva. Another candidate, KER-012, is being developed for conditions related to bone loss, such as osteoporosis and osteogenesis imperfecta, and for pulmonary arterial hypertension. Founded in 2015, Keros Therapeutics is headquartered in Lexington, Massachusetts.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, specifically anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapy aimed at treating anemia caused by elevated hepcidin levels, as well as fibrodysplasia ossificans progressiva. Another candidate, KER-012, is being developed for conditions related to bone loss, such as osteoporosis and osteogenesis imperfecta, and for pulmonary arterial hypertension. Founded in 2015, Keros Therapeutics is headquartered in Lexington, Massachusetts.

Lendbuzz, Inc. operates an innovative car financing platform that utilizes machine learning algorithms to assess the creditworthiness of individuals, particularly those with thin or no credit history. Founded in 2015 and based in Boston, Massachusetts, the company focuses on providing financing solutions for consumers who are often underserved by traditional banks, including international students, foreign professionals, and expatriates. By analyzing a range of background information—such as employment, education, and financial history—Lendbuzz is able to extend loans and refinancing options with favorable terms, regardless of credit score or the presence of a social security number. The platform partners with auto dealerships to facilitate access to financing, allowing consumers to purchase vehicles while enabling dealerships to serve a broader and more diverse client base.

ARTSaVIT is a biopharmaceuticals company developing a cancer drug.

Digma Medical is a clinical stage medical device company established in 2013, focused on innovating treatments for Type-2 Diabetes and related metabolic syndromes, including NASH. The company is developing the DiaGone™, an endoscopic and disposable device that employs advanced laser technology to treat the duodenum without the need for an implant. The Duodenal Glycemic Control™ procedure, which lasts approximately 30 minutes, allows gastroenterologists to use the DiaGone™ to enhance the body's ability to regulate glucose levels. This approach aims to offer patients the potential for long-term remission from Type-2 Diabetes and other metabolic conditions, thereby improving their overall quality of life and health outcomes. Supported by prominent venture capital firms, Digma Medical is dedicated to advancing effective therapies for diabetes management.

Oncorus, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative viral immunotherapies for cancer treatment. The company's lead candidate, ONCR-177, utilizes an oncolytic herpes simplex virus type 1 platform and is currently in Phase I clinical trials aimed at treating various cancers. In addition to ONCR-177, Oncorus is advancing the ONCR-GBM program for brain cancer and exploring synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has entered a collaboration with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 in combination with Merck’s immunotherapy. Founded in 2015 and headquartered in Cambridge, Massachusetts, Oncorus is committed to advancing cancer care and has pledged to support cancer research and healthcare initiatives in developing regions through corporate philanthropy.

BioSight is a biopharmaceutical company focused on developing innovative cancer-targeted chemotherapy pro-drugs. Founded in 2000 and based in Lod, Israel, BioSight has developed a technology known as S2DOT, which allows for the targeted delivery of chemotherapy drugs directly into cancer cells. This approach significantly reduces the systemic toxicity often associated with traditional chemotherapy treatments. The company’s lead product is a non-toxic conjugate of cytarabine and asparagine, designed specifically for the treatment of acute myeloid leukemia. Through its research and development efforts, BioSight aims to provide safe and effective therapeutic options for patients suffering from hematological malignancies and disorders.

Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Utilizing a proprietary platform that integrates computational biology, genomics, and metabolomics, Metabomed identifies specific metabolic alterations associated with cancer growth. The company's small molecule drugs are designed to halt the proliferation of reprogrammed cancer cells, which allows oncologists to initiate treatment more swiftly and enhances the chances of successful patient outcomes while minimizing harm to healthy tissues. Through its innovative approach, Metabomed aims to advance cancer treatment by addressing the metabolic characteristics that distinguish cancer cells from normal cells.

Sol-Gel Technologies Ltd. is a clinical-stage specialty pharmaceutical company based in Ness Ziona, Israel, focused on developing and commercializing topical dermatological drug products. The company employs a proprietary microencapsulation delivery system to enhance the effectiveness of its formulations. Its lead product candidates include Twyneo and Epsolay, both of which have completed Phase II clinical trials for acne vulgaris and papulopustular rosacea, respectively. Additional candidates in development include SGT-210, an epidermal growth factor receptor inhibitor for palmoplantar keratoderma and non-melanoma skin cancer, as well as treatments for psoriasis. Sol-Gel is also engaged in the development of generic topical dermatological products and has established collaborations with Perrigo and Douglas Pharmaceuticals for this purpose. Founded in 1997, the company continues to innovate within the dermatology sector.

Quiet Therapeutics Ltd. is a biotechnology company based in Ness Ziona, Israel, that specializes in the discovery and development of cancer therapies. Founded in 2009, the company utilizes its proprietary GAGomer technology, a nanoparticle-based delivery system, to specifically target tumor cells. This innovative approach allows for the delivery of therapeutic agents, including expression plasmids, RNA therapeutics, and small molecules, aimed at inducing the death of cancer cells. By focusing on oncology and inflammation, Quiet Therapeutics aims to expand the range of drug targets and improve treatment outcomes for patients.

cCAM Biotherapeutics Ltd. is a clinical-stage company focused on the discovery and development of novel immunotherapies for cancer treatment. Founded in 2010 and based in Misgav, Israel, the company is advancing its lead candidate, CM-10, an immunomodulatory antibody designed to counteract the immunosuppressive effects of CEACAM1, a protein utilized by cancer cells. By inhibiting this protein, CM-10 aims to stimulate a cancer-specific immune response, targeting various malignancies such as melanoma, non-small-cell lung cancer, bladder cancer, gastric cancer, colorectal cancer, and ovarian cancer. cCAM Biotherapeutics is dedicated to developing innovative therapeutic solutions to improve outcomes for cancer patients.

The value of connecting disparate datasets is immense, yet much of this potential remains untapped. Imagine the transformative possibilities: pharmaceutical companies sharing data to design better drugs and evaluate their real-world value, hospitals and HMOs diagnosing rare diseases faster, or financial institutions collaborating to combat financial crime. Rhino Federated Computing makes this vision a reality. Our federated computing platform, powered by advanced edge-computing and federated learning technologies, enables organizations to train and deploy AI models on massive, distributed datasets—without sharing sensitive information or compromising data privacy and sovereignty. This breakthrough approach was pioneered by our co-founder and CEO, Dr. Ittai Dayan, a recognized leader in the field whose work includes a landmark Nature Medicine publication in 2021.